Cogent Biosciences, Inc.
NASDAQ:COGTBiotechnology
+$0.88 today
- Market cap
- $4.83B
- Beta
- 0.35
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$5.26
Volume 1.68M
Average 2.15M
Returns on capital
Cogent Biosciences, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-51.7%
avg -57.6%
ROIC
-38.1%
avg -53.3%
ROA
-35.1%
avg -42.4%
Analysis
ROA is currently the strongest return metric at -35.1% versus its period average of -42.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Andrew R. Robbins | President, Chief Executive Officer & Director | USD 1.32M | 50 | 160.00K | 0.09% |
Jessica Sachs | Chief Medical Officer | USD 896.62K | 51 | 133.94K | 0.08% |
John Edward Robinson | Chief Scientific Officer | USD 868.74K | 52 | 140.00K | 0.08% |
John L. Green | Chief Financial Officer & Principal Accounting Officer | USD 834.28K | 46 | 131.83K | 0.08% |
Cole Pinnow | Chief Commercial Officer | USD 754.6K | 51 | 65.00K | 0.04% |
Abb Hayden | Senior Vice President of Sales | — | — | — | — |
Brad Barnett | Chief Technology Officer | — | — | — | — |
Evan D. Kearns | Chief Legal Officer & Corporate Secretary | — | 46 | — | — |
Christi Waarich | Senior Director of Investor Relations | — | — | — | — |
Erin Schellhammer | Chief People Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 19, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
8
$383.89M
Net Transaction Value
−$383.89M
Net selling
Most Active
Morris Arlene
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 27, 26Aug 27, 2026 | Morris Arlene Direct | Sell | $1.6M$1,570,830.28 |
| Aug 27, 26Aug 27, 2026 | Morris Arlene Direct | Sell | $118.7K$118,662.68 |
| Mar 31, 26Mar 31, 2026 | Fairmount Funds Management LLC Indirect | Sell | $242.6M$242,620,000.00 |
| Jan 22, 26Jan 22, 2026 | Fairmount Funds Management LLC Indirect | Sell | $127.4M$127,400,000.00 |
| Dec 26, 25Dec 26, 2025 | Kearns Evan Direct | Sell | $2.5M$2,515,500.00 |
| Dec 26, 25Dec 26, 2025 | Green John L. Direct | Sell | $3M$2,978,360.00 |
| Dec 26, 25Dec 26, 2025 | Sachs Jessica Direct | Sell | $3.2M$3,198,245.40 |
| Dec 26, 25Dec 26, 2025 | Robinson John Edward Direct | Sell | $3.5M$3,486,600.00 |
Summary
Insiders reported 0 buys worth $0.00 and 8 sells worth $383.89M over the last 12 months. That adds up to net selling of $383.89M. Morris Arlene was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Cogent Biosciences, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about COGT's management, answered from reported figures.
Who manages COGT?
Cogent Biosciences, Inc. (COGT) lists 10 active executives. The top listed executive is Jessica Sachs, Chief Medical Officer.
Are COGT insiders buying or selling?
Recent insider activity shows net selling of $229.15M.
Continue the stock analysis
Jump to another research area for this company.